David González - Concepedia

Author

David González

Royal Marsden NHS Foundation Trust ORCID

Also Known As

Anton W. Langerak, D Gonzalez, D González, D. Gonzalez, D. González, Daniel Alejandro Mantilla Gonzalez, Daniela Vlasak Gonzalez, Danáe Arancibia González, David Alejandro Gonzalez, David Gonzalez

117

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden NHS Foundation Trust Royal Marsden Hospital Institute of Cancer Research Queen's University Belfast Royal Bournemouth Hospital

About

David González is an author at Royal Marsden NHS Foundation Trust specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	1.9K
2	Health Sciences	4	4	275
3	Cell Biology	3	3	100
4	Education	1	1	155
5	Cognitive Science	1	1	155

David González

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Ian Chau, David Cunningham, David González, The Lancet Oncology OncologyOpen-label Phase 3Cancer ManagementPathologyCancer Treatment	2013	723
Mismatch Repair Deficiency, Microsatellite Instability, and Survival Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt, JAMA Oncology	2017	509
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936 Paul Evans, Ch Pott, Patricia J.T.A. Groenen, Leukemia B-cell MalignanciesLymphoid NeoplasiaHematological MalignancyMedicineImmunology	2006	296
Mutational Status of the <i>TP53</i> Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial David González, Pilar Martı́nez, Rachel Wade, Journal of Clinical Oncology	2011	263
Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis Andrew G. Nicholson, David González, Pallav L. Shah, Journal of Thoracic Oncology Egfr Mutation AnalysisMedicineMultiple Pulmonary NoduleEgfr StatusPathology	2010	213
The role of vision for online control of manual aiming movements in persons with autism spectrum disorders Cherylm. Glazebrook, David González, Steve Hansen, Autism Motor SkillAutism Spectrum DisordersEducationMotor ControlMotor Difficulty	2009	155
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma Matthew Jenner, Paola Leone, Brian A. Walker, Blood	2007	138
Primary Pulmonary Myxoid Sarcoma With EWSR1-CREB1 Fusion Khin Thway, Andrew G. Nicholson, Kay Lawson, The American Journal of Surgical Pathology Gene FusionEwsr1-creb1 FusionRecurrent Fusion GeneMultiple Pulmonary NoduleSurgical Pathology	2011	137
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications Vasileios Bikos, Nikos Darzentas, Anastasia Hadzidimitriou, Leukemia Ontogenetic ImplicationsImmunogeneticsLymphoid NeoplasiaMedicineGenetics	2012	119
Recurrent CDKN1B (p27) mutations in hairy cell leukemia Sascha Dietrich, Jennifer Hüllein, Stanley Chun-Wei Lee, Blood	2015	107

Page 1